ICH GCP R3 is now in English & EU languages. Book Now
  • Preclinical & Laboratory Foundations
  • Phase I – First-in-Human Trials
  • Phase II & III – Efficacy & Pivotal Trials
  • Clinical Trials Foundation PathNew
  • Regulatory Submission & Approval
Preclinical & Laboratory Foundations - courses at £229
  • Good Laboratory Practice (GLP)
  • 21 CFR Part 58 — Good Laboratory Practice (GLP) for Nonclinical Laboratories
  • OSHA Laboratory Safety Training
  • Laboratory Management Systems ISO/IEC 17025:2017
  • Computer System Validation - Validation, Data Integrity & Compliance (GAMP 5 & Annex 11)
  • Qualification Validation Training
  • Cleaning Validation
  • ISO 9001:2015 - Quality Management System for Pharmaceuticals

About

A narrative-driven orientation to the Pharmacovigilance & Safety Writing Specialist Path — built as a guided career experience for the ten-module learning track, not a compliance refresher. Across six cinematic chapters learners follow the discipline from the writer's seat: case narratives, aggregate reports, signal evaluations, Risk Management Plans, CAPAs and quality writing, plus AI in pharmacovigilance. Composite personas — Maya, Daniel, Priya and Aisha — anchor each chapter; real-world case studies (Vioxx, SGLT2 DKA, GLP-1 pancreatitis, EMA Article 31 referrals) show why the writing matters. Designed to feel premium, practical and career-oriented.

Designed for senior nurses, pharmacists, life-science graduates, pharmacovigilance operations staff, case processors stepping up into a writing role, and career-changers from any background curious about drug-safety medical writing as a destination. On completion you will distinguish PV operations from specialist safety writing, name the ten output types this learning path develops, describe a realistic week in the life of a drug-safety writer, locate the Whitehall modules that underpin each output, choose where to start in the path based on your current role, and articulate the case for safety writing as a high-value career destination. Aligned to EMA GVP, MHRA pharmacovigilance guidance, FDA post-marketing rules, the ICH E2 safety guideline family, CIOMS narrative conventions and EMWA / AMWA professional standards.

Course Syllabus

  1. PV from the writer's seat
  2. Ten outputs of a safety writer
  3. Meet Maya — and three others
  4. The path in one picture
  5. What success looks like
  6. Where this path fits in Whitehall
  7. A first taste of the craft
  8. Three commitments to ask of yourself

  1. Why narratives exist
  2. The CIOMS shape
  3. Causality in two views
  4. Seriousness and expectedness
  5. The five rewrite triggers
  6. Five-pass reviewer checklist
  7. Special cases
  8. From draft to inspection-ready

  1. What a signal is
  2. The signal detection lifecycle
  3. Writing the signal validation memo
  4. Writing the signal evaluation report
  5. Literature monitoring
  6. Signal documentation in PSURs
  7. Risk assessment, briefly
  8. How signal writers grow

  1. The aggregate report family
  2. The PBRER skeleton
  3. Ownership and roles on a PSUR
  4. Inside Section 16
  5. DSURs — what changes
  6. The aggregate-reporting calendar
  7. Quality, consistency and inspection-readiness
  8. How aggregate writers grow

  1. The RMP, briefly
  2. The safety specification
  3. The PV plan and risk minimisation
  4. From RMP to label
  5. Deviation reports
  6. CAPAs
  7. SOPs and the quality writing surround
  8. How quality writers grow

  1. AI in pharmacovigilance in 2026
  2. Working with AI as a writer
  3. The senior writer's arc
  4. The Whitehall ecosystem map
  5. The 30 / 90 / 365-day plan
  6. What success looks like
  7. Why this work matters
  8. Closing reflection
  9. Course complete

Course Benefits

Benefits cpd_points icon
CPD Points

Gain Continuing Professional Development (CPD) Points, accredited by The Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. These can be used to count towards the distance learning element of any scheme that comes under the umbrella of The Academy of Medical Royal Colleges or any other scheme for which there is mutual recognition.

Benefits certification icon
Certification

Receive a personal certificate to show your subject knowledge on course completion.

Benefits affordable icon
Affordable

You get excellent value through our cost-effective prices. We can also offer you group discounts on larger purchases.

Benefits flexible icon
Flexibility

The course saves you time through the convenience of online availability. This lets you complete the interactive course at your own comfort.

Benefits up_to_date icon
Keep Up to Date

You will stay up to date with any changes to EMA GVP, MHRA pharmacovigilance guidance, FDA post-marketing rules, the ICH E2 safety guidelines, CIOMS narrative conventions and EU Risk Management Plan requirements, as this course is continuously monitored, reviewed and refreshed.

Benefits industry_experts icon
Learn from Industry Experts

The course content has been developed by Whitehall medical-writing faculty drawing on EU, UK and US regulator practice, CIOMS narrative conventions and EMWA / AMWA professional standards, so career-changers and new entrants build inspection-ready foundations they can apply on the job from day one.


Our Certified Customers

novartis
NHS
takeda
roche
dhl

Learner Rating & Reviews

4.7
Average Rating
536 global ratings
87.0%
5.0%
3.0%
3.0%
2.0%
RC

Working with Whitehall training for the last two years of partnership has been a very successful experience – I have fast access to all the GCP course...

SM

I have finalised the demo for the ICH-GCP E6 R3 refresher course. Overall, I liked the content and the interface. I also want to thank Whitehall Train...